Please try another search
For the nine months ended 30 September 2015, Zeltia SA revenues increased 8% to EUR126.8M. Net income before extraordinary items decreased 56% to EUR7.8M. Revenues reflect Biopharmaceuticals segment increase of 14% to EUR69.7M, Chemicals segment increase of 2% to EUR56.3M. Net income was offset by Research/Development increase of 23% to EUR45.7M (expense), Selling Expense increase of 9% to EUR35.3M (expense).
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Revenue | 42.45 | 49.4 | 34.97 | 32.74 |
Gross Profit | 29.98 | 35.84 | 27.37 | 26.99 |
Operating Income | 4.59 | -1.57 | 7.97 | -1.4 |
Net Income | 4.36 | -3.21 | 6.54 | -4.41 |
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Assets | 245.69 | 223.11 | 205.77 | 201.39 |
Total Liabilities | 164.95 | 146.76 | 135.82 | 137.51 |
Total Equity | 80.74 | 76.35 | 69.94 | 63.88 |
Period Ending: | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -6.55 | -10.42 | 0.55 | 22.11 |
Cash From Investing Activities | 2.24 | 5.66 | 0.34 | -22.31 |
Cash From Financing Activities | 27.29 | 11.15 | -2.49 | -5.7 |
Net Change in Cash | 22.98 | 6.39 | -1.6 | -5.91 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review